$1.75
+0.11%Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
No Revenue Data
NMRA has not reported any revenue values in the available annual periods.
NMRA • NASDAQ
| Neumora Therapeutics, Inc. Common Stock Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
REVENUE | ||||||
GROSS PROFIT | ||||||
(5M) | (0.0) | (668K) | (0.0) | (0.0) | (0.0) | |
-5M | 0.0 | -668K | 0.0 | 0.0 | 0.0 | |
OPERATING INCOME | ||||||
(236.2M) | (263.5M) | (187.5M) | (135.9M) | (237.3M) | (95.5M) | |
(60.1M) | (62.5M) | (44.8M) | (31.1M) | (24.5M) | (8.4M) | |
(176.1M) | (200.9M) | (142.7M) | (104.7M) | (212.8M) | (87.1M) | |
-241.2M | -263.5M | -188.2M | -135.9M | -237.3M | -95.5M | |
PRE-TAX INCOME | ||||||
(3.2M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
5.1M | 19.9M | 16.6M | 4.6M | 0.0 | 0.0 | |
4.4M | 19.9M | -47.5M | 5M | 11K | -3.8M | |
-236.8M | -243.6M | -235.7M | -130.9M | -237.3M | -99.3M | |
NET INCOME | ||||||
(130K) | (178K) | (268K) | (0.0) | (0.0) | (0.0) | |
-236.9M | -243.8M | -235.9M | -130.9M | -237.3M | -99.3M |
NMRA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 27, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 17, 2026 | May 27, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 11, 2026 | February 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 05, 2026 | January 05, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 21, 2025 | November 17, 2025 | 2025 |
Continue your NMRA research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.